CLN-978 is an advanced, highly potent CD19 x CD3 bispecific T-cell engager designed to target and destroy harmful cells by binding to CD19 on B cells and CD3 on T cells. It is engineered to have a ...

The FDA granted breakthrough therapy designation to CLN-081 for treatment of certain patients with non-small cell lung cancer.The designation applies to use of the agent by patients with locally ...